Combination of the soluble antagonists DKK1 and SOST inhibition using a bispecific antibody strategy provided superior increases in bone mass and fracture repair in rodents compared to single treatment approaches.(18) We therefore applied this approach in our 5TGM1 murine model of myeloma, targeting both the LRP6 receptor and the soluble Wnt antagonist DKK1. This evidence concerns the gene DKK1 and plasma cell myeloma.